Pixyl, a start-up developing innovative software solutions for neurologists and radiologists, has completed an investment round of €500k with IT-Translation Investment, Crédit Agricole and Davycrest Nominees, to fund growth and innovation.
Pixyl provides actors in clinical trials (sponsors, CROs, neurologists and radiologists) with increased confidence in the quantitative analysis of neurological images, thereby improving decision-making and and optimizing resource management (recruitment and training of reviewers) in the clinical study.
The software Pixyl.Neuro automatically extracts biomarkers related to stroke, traumatic brain injury, multiple sclerosis and other neurodegenerative diseases. These biomarkers are crucial in measuring treatment efficacy, and establishing disease diagnosis, prognosis and follow-up. Pixyl.Neuro is currently used in numerous clinical studies, managed by world-renowned experts in neurology.
“Neuroimaging biomarkers are increasingly important for doctors, researchers, and bio-pharmaceutical laboratories faced with demand for greater precision and reproducibility, amid rising costs.”, says Dr. Senan Doyle, CEO of Pixyl. “Pixyl delivers reliable and cost-effective information to improve the quality of patient care”.
According to Benoît Georis of IT-Translation “We were seduced by the capabilities of the technology, a world first. Thanks to the analysis of voxels (3D pixels) combined with artificial intelligence techniques, the precision is remarkable. Automation will make it possible to significantly increase the size of study cohorts and ultimately improve the development of new therapies“.
According to Sabrina Kouidri of Crédit Agricole Sud Rhône Alpes Capital “We are convinced that Pixyl will capture a significant part of the fast-growing neurological diagnostic assistance market. We are confident in the team, who have adopted promising strategic axes for growth”.
Leave a Reply
Want to join the discussion?Feel free to contribute!